Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 05 Mar 2019 Planned End Date changed from 30 Aug 2019 to 28 Feb 2022.
- 05 Mar 2019 Planned primary completion date changed from 30 Aug 2019 to 28 Feb 2020.
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.